The overlapping development programs for first-generation larotrectinib and second-generation LOXO-195 signal narrowing drug development timelines in the era of precision oncology.
In order to be eligible for the drug, patients must have NTRK fusions, which may be determined via various tests including NGS and FISH.
In development for several years, PORTIN is now being deployed as a single point of reference for all genotype and phenotype data at Bayer's research sites.
The partners have been working together since 2013 to use cancer and cardiovascular genomics for drug discovery.
The Boston-based synthetic biology company will use the proceeds to grow Bioworks3, its new organism foundry, and to expand into new markets.
Backed by €19 million in EU funding, the initiative, called BigData@Heart, will create a research platform that could change the way cardiovascular diseases are diagnosed and treated.
Both deals should advance Ginkgo's custom microbe business as it expands into consumer goods markets such as cosmetics, nutrition, and food.
Companion diagnostics developed under the deal will be based on RNAscope and immunohistochemistry technology.
The deal gives Bayer access to the T2 Magnetic Resonance technology for drug discovery and biomarker research in certain hemostasis programs.
The deal with ERS Genomics, a commercialization vehicle for Emmanuelle Charpentier's patents, gives the Bayer LifeScience Center access to CRISPR/Cas9 genome editing.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.